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YiQiFuMai Powder Injection (YQFM) is a re-developed preparation based on the well-known traditional
Chinese medicine formula Sheng-mai-san. It has been widely used for the treatment of cardiovascular
disease with deﬁnite clinical efﬁcacy in China, but its bioactive molecules remain obscure. In this study,
an effective method has been employed as a tool for screening active components in YQFM, using human
umbilical vein endothelial cells (HUVECs) extraction and liquid chromatography coupled with electro-
spray ionization quadrupole time-of-ﬂight tandem mass spectrometry (Q-TOF MS/MS). Nine compounds,
which could interact with HUVECs, were identiﬁed as ginsenosides Rb1, Rc, Rb2, Rd, 20(S)-Rg3, 20(R)-
Rg3, Rk1/Rg5 and schisandrin by comparing with reference substances or literature. In vitro assays
showed that schisandrin at concentrations of 10e100 mM protected HUVECs from hypoxia/reoxygenation
(H/R) injury, increased cell viability, nitric oxide (NO) content and decreased lactate dehydrogenase
(LDH) leakage, malonaldehyde (MDA) content and ROS generation. Moreover, schisandrin pretreatment
inhibited cell apoptosis, as evidenced by inhibiting activation of caspase-3 and increasing the Bcl-2/Bax
ratio. These data indicate that HUVECs biospeciﬁc extraction coupled with HPLC-ESI-Q-TOF-MS/MS
analysis is a reliable method for screening potential bioactive components from traditional Chinese
medicines. Meanwhile, the vascular endothelium protective property of schisandrin might be beneﬁcial
for the treatment of cardiovascular disease.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Traditional Chinese medicines (TCMs) are attracting increasing
attention, not only due to their reliable curative efﬁcacy and long
history of clinical trials, but also because TCMs can serve as an
important source of bioactive compounds in the search for new
drugs. However, the components of TCMs are usually complex
mixtures, containing hundreds or even thousands of different
compounds, whereas only a few compounds are responsible for
the pharmacological effects through complicated synergistic or
integrated actions. In most cases, biologically active compounds in.
acological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).TCMs are not or only partially known. Therefore, it is exceedingly
important to investigate the bioactive components and therapeutic
mechanisms for the exploration and elucidation of TCMs (1,2).
Nowadays, the interaction of drugs with target cells has been
successfully employed as a screen for bioactive components in
TCMs (3,4). Meanwhile, HPLC-DAD-Q-TOF-MS/MS, a powerful
technique for identiﬁcation of unknown molecules, has been
widely applied to the modern pharmaceutical analysis of TCMs (5).
So it becomes practicable to explore the biospeciﬁc active compo-
nents from TCMs by extracting with cells and then identifying with
HPLC-DAD-Q-TOF-MS/MS technology.
The YiQiFuMai Powder Injection (YQFM) is a traditional Chinese
medicine for the treatment of cardiovascular disease (6,7). It
has been re-developed based on the well-known TCMs formula
Sheng-mai-san, which is composed of Panax ginseng C.A. MEY.,r B.V. on behalf of Japanese Pharmacological Society. This is an open access article
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(Turcz.) BAILL (1:3:1.5). Considerable clinical trials have indicated
that YQFM can be widely used for the treatment of chronic heart
failure with better efﬁcacy and fewer side effects compared with
standardmedical treatments (8). It has also been suggested that the
three herbs of YQFM have beneﬁcial effects in the treatment of the
cardiovascular diseases and regulation of blood vessel function
(9e12). Although both clinical and experimental studies demon-
strate the prophylactic or therapeutic efﬁcacy of YQFM, the actual
bioactive molecules have not yet been well identiﬁed. Various
pharmacological studies showed that some bioactive compounds
from Ginseng Radix Et Rhizoma Rubra, such as ginsenoside Rg1,
Rb1, and Rg3, have curative effects in coronary artery disease, car-
diac hypertrophy, heart failure, cardiac energy metabolism, cardiac
contractility and arrhythmia, and could represent the active com-
ponents of YQFM (13e17). Schisandrin B has been reported to be
one of the active chemicals with activities improving cardiac
function and attenuating myocardial remodeling after myocardial
infarction in mice (18). However, it is not fully known about the
molecules responsible for the cardiovascular protective effect of the
other two herbs.
On the other hand, endothelial dysfunction is a key event in
cardiovascular disease. Endothelial cells release substances such as
nitric oxide (NO), which are essential for controlling vascular
growth, vasomotor reactivity, coagulation and inﬂammatory re-
sponses. During normal physiological conditions, endothelial cells
appear able to regulate cardiac contractility, myocardial meta-
bolism and heart rate. Endothelial damage can lead to inﬂamma-
tion, leukocyte and platelet extravasation, vascular damage,
resulting myocardial infarction or acute coronary syndromes
(19e21). Furthermore, the excessive apoptosis of the endothelial
cells induced by hypoxia/reoxygenation (H/R) stress are closely
associated with the cardiovascular diseases. Therefore, blockage of
pro-apoptotic pathways in the endothelial cells has been consid-
ered as an attractive therapeutic strategy to prevent or ameliorate
the progression of the cardiovascular diseases (22,23). In the pre-
sent study, in order to ﬁnd out the vascular endothelium protective
components from YQFM, ﬁrstly HUVECs, were co-cultured with
YQFM to extract the potential cardiovascular active components.
Then HPLC-ESI-MS/MS analysis was employed for the structure
elucidation of the components extracted in HUVECs. Eventually, to
verify the vascular protective activity, some molecules bounded to
HUVECs were investigated by cell viability assay and anti-apoptosis
assay.
2. Materials and methods
2.1. Reagents and materials
YQFM was provided by Tasly Pharmaceutical Co., Ltd. (Tianjin,
China) with the batch number of 20121210, which is the prescrip-
tion of Panax ginseng C.A. MEY., Ophiopogon japonicus (Thunb.) KER-
GAWL and Schisandra chinensis (Turcz.) BAILL. The specimen was
identiﬁed by professor Bo-Yang Yu (Specimen No. 20121210) and
deposited in the Herbarium of Department of Traditional Chinese
Medicine of China Pharmaceutical University. Reference substances
of ginsenoside Rb1 and schisandrin were purchased from Nanjing
Zelang Bio-Technology Co., Ltd. (Nanjing, China), Rc, Rb2, Rd, 20(R)-
Rg3 were kindly given by Dr. JingrongWang at Macau University of
Science and Technology. The purity of each compound was deter-
mined to be higher than 98% by HPLC. HPLC-grade acetonitrile was
purchased from Tedia (Fairﬁeld, OH, USA). Deionized water for
HPLC-MS analysis was prepared using a Milli-Q system (Milford,
MA, USA). Formic acid (Aladdin Chemistry Co. Ltd) was used for all
analyses. Methanol for sample extraction was from HanbonReagent Company (Jiangsu, China). Dulbecco's modiﬁed Eagle
medium (DMEM) and fetal bovine serum (FBS) were from GIBCO/
BRL (Life Technologies, California, USA). 3-[4,5-Dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) was from AMRESCO
(Cleveland, OH, USA) and phosphate-buffered saline (PBS, pH7.4)
was prepared in our laboratory. All other chemicals were of
analytical grade. All solvent and samples were ﬁltered through
0.22 mm membranes before use.
2.2. Preparation of YQFM and standard samples
YQFM (Batch No. 20121210) was provided by Tasly Pharma-
ceutical Co., Ltd. (Tianjin, China). It comprises of the ethanol extract
(78 C) of Panax ginseng C.A. MEY., water extract (100 C) of
Ophiopogon japonicus (Thunb.) KER-GAWL and Schisandra chinensis
(Turcz.) BAILL combined in the ratio of 1:3:1.5. The yield of extracts
is 23.64%, following by precision processes of multiple ﬁltering,
lyophilizing, and aseptic packaging. Then the YQFM was dissolved
in 5mL DMEMmedium (pH¼ 7.4) to make the 100mg/mL solution
and ﬁltered through a 0.22 mm membrane, then the ﬁltrate was
used for HUVECs biospeciﬁc extraction and HPLC-Q-TOF-MS/MS
analysis (sample A5 and B5). For qualitative analysis, a stock solu-
tion of reference substances was prepared in methanol and stored
at 4 C until use (sample A3 and B3).
2.3. HUVECs extraction and sample preparation
HUVECs line was purchased from Shanghai Institute of Cell
Biology, Chinese Academy of Sciences (Shanghai, China). HUVECs
were grown at 37 C and 5% CO2 cultured in 10% FBS DMEM me-
dium. YQFM prepared as afore mentioned was added when the cell
density reached 90%. The drug solution was removed after incu-
bation for 1 h and the 10-cm dish was washed with 8 mL PBS for 5
times to remove unbound components, collected the last 1.5 mL
PBS eluate as a control for HPLC-MS analysis (sample A1 and B1).
Finally, HUVECs were denatured and extracted with 4 mL of 80%
methanol by ultrasonic extraction to liberate components bound to
the cells. The desorption eluate was centrifugated and the super-
natant was condensed to 100 mL for HPLC-MS analysis (sample A4
and B4). The control sample, in which YQFM was replaced by
DMEM, was prepared using the same procedures as described
above (sample A2 and B2).
2.4. Chromatographic and mass spectrometric conditions
HPLC-DAD-Q-TOF-MS/MS analysis was carried out using an
Agilent series 1290 Inﬁnity HPLC instrument (Agilent, Waldbronn,
Germany) coupled with an Agilent 6530 Q-TOF mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA) equipped with an
electrospray (ESI) interface. The mobile phase consisted of aceto-
nitrile (A) and water-0.1% acetic acid (B), and the gradient elution
conditions were: 0e30 min, 8e18% A; 30e80 min, 18e50%
A; 80e115 min, 50e100% A and then returned to the initial
condition. The ﬂow rate was 1.0 mL/min. Chromatographic sepa-
ration was carried out at 30 C on an Alltima C18 column
(4.6 mm  250 mm, I.D., 5 mm, Serial No. 213040116, GRACE-
Alltech, USA). The DAD detector scanned from 190 to 400 nm,
and the samples were detected at 203, 254 and 296 nm. The MS
detection parameters were optimized as follows: drying gas
temperature, 350 C; drying gas (N2) ﬂow rate, 9.0 L/min;
fragmentor voltage, 120 V; nebulizer, 45 psig and capillary, 3000 V;
skimmer, 65 V; Oct RFV, 750 V. The sample collision energy was set
at 20e40 V. All the acquisition and analysis of data were controlled
by MassHunter software (Agilent Technologies). Mass spectra were
recorded in the range of m/z 100e2000 with accurate mass
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positive (Fig. 1A) and negative (Fig. 1B) modes to give abundant
information for structural identiﬁcation.
2.5. HUVECs damage induced by H/R
The H/R model was established according to the method with
slight modiﬁcations (24). Brieﬂy, HUVECs were incubated under
hypoxia using a 94% N2, 5% CO2 and 1% O2 for 4 h in a humidiﬁed N2/
CO2 incubatorand then ina standard incubatorwith5%CO2 innormal
atmosphereat37 C for 2h.Cellswerepretreatedwith the compound
at 0.1e100 mM for 12 h before subjecting to H/R. The control groups
were treated without the compound and H/R treatment.
2.6. Cell viability assay and measurement of LDH activity
HUVECs growing exponentially were trypsinized and then
approximately 8000 cells/well were seeded into 96-well plates.
After the experimental treatment, HUVECs were incubated with
MTT at a ﬁnal concentration of 0.5 mg/mL for 3 h at 37 C. Then, the
mediumwas discarded and 150 mL DMSOwas added to dissolve the
formazan crystals. The absorbance was read at 570 nm with a
reference wavelength of 650 nm and cell viability was expressed as
percentage of absorbance to control values. To further measure the
extent of cell injury, the LDH activity was also tested. At the end of
the incubation period, the culture supernatants were collected. The
activity of LDH was detected at 490 nm according to the LDH assay
kit (Beyotime Institute of Biotechnology, Shanghai, China).
2.7. Measurement of nitric oxide (NO), the malondialdehyde (MDA)
and intracellular ROS
The content of NO and MDA were determined with assay kits
(Jiancheng Bioengineering Research Institute, Nanjing, China) ac-
cording to the manufacturer's instructions. In brief, cells wereFig. 1. Detection of YQFM HUVECs-binding molecules by HPLC-DAD-Q-TOF-MS/MS. (A) to
desorption elute, A3 standard sample solution, A4 the desorption elute, A5 YQFM, 1 schisand
blank desorption elute, B3 standard sample solution, B4 the desorption elute, B5 YQFM, 2
senoside Rg3, 7 20(R)-ginsenoside Rg3, 8/9 ginsenoside Rk1/Rg5.harvested by trypsinization and cellular extracts were lysed with
RIPA lysis buffer. Then lysed cells were centrifuged and the super-
natant was subjected to the measurement of MDA, NO levels and
the protein contents. MDA and NO levels were then normalized
to milligram protein. ROS levels were determined using 20, 70-
dichloroﬂuorescein diacetate (DCFH-DA, Jiancheng Bioengineering
Research Institute, Nanjing, China). Cells were incubated for 30 min
with DCFH-DA (10 mmol/L), then the cells were washed with PBS
and visualized by ﬂuorescence microscopy.
2.8. Western blot analysis
As reported (25), after washing with the ice-cold PBS, HUVECs
were lysed with RIPA lysis buffer (Vazyme Biotech, Nanjing, China)
supplemented with protease inhibitor (Vazyme Biotech, Nanjing,
China). Equal amount of proteins were separated on 12.5% SDS-
PAGE and transferred to PVDF membrane (Millipore Corporation,
Billerica, MA, USA). The membranes were blocked with 3% BSA in
TBS/T and stained with primary antibodies against caspase-3, Bax,
Bcl-2 and b-actin (dilution 1:1000, 1:1000, 1:1000, 1:4000,
respectively; Cell Signaling Technology, Boston,MA, USA) overnight
at 4 C. Membranes were then probed with peroxidase conjugated
secondary antibody at a 1: 8000 dilution (Bioworld Technology,
Nanjing, China). The antigeneantibody complexes were then
detected with chemiluminescene (ECL) reagent (Vazyme Biotech,
Nanjing, China). The immunoreactive bands were visualized by
ChemiDoc™MP System (Bio-Rad) and analyzed using Image Lab™
Software (version 4.1, Bio-Rad).
2.9. Statistical analysis
All experiments were performed in triplicate and data were
expressed as the mean ± standard deviation. Statistical analysis
was carried out using Student's two-tailed-t-test for comparison
between two groups and one-way analysis of variance (ANOVA),tal ion current (TIC) in positive ion mode: A1 the ﬁnal washing eluate, A2 the blank
rin. (B) total ion current (TIC) in negative ion mode: B1 the ﬁnal washing eluate, B2 the
ginsenoside Rb1, 3 ginsenoside Rc, 4 ginsenoside Rb2, 5 ginsenoside Rd, 6 20(S)-gin-
F. Li et al. / Journal of Pharmacological Sciences 129 (2015) 1e84followed by Dunnett's test when the data involved three or more
groups. P < 0.05 was deﬁned as signiﬁcant.
3. Results
3.1. HUVECs-binding components of YQFM
It is critical to completely wash out the compounds which not
specially binding with HUVECs, after the components have com-
binedwith the receptors on HUVECs, generallywashedwith PBS for
several times to scour off the possible non-selectively combining
components. The eluates were discarded except for the last one,
which was collected as contrast for HPLC-MS analysis. As shown in
Fig. 1, nine principal peaks were identiﬁed in the extraction of
HUVECs (A4, B4) by comparing standards (A3, B3) fragmentation
behavior and the retention time with YQFM (A5, B5). No compa-
rable peaks were detected in the ﬁnal washing eluate (A1, B1) and
blank desorption eluate (A2, B2). Therefore, it was assumed that
these nine components were extracted by some receptors or other
targets of HUVECs in analogical physiological condition, which
indicated that these binding molecules as potential vascular
endothelium protective compounds of YQFM.
3.2. HPLC-ESI-MS/MS analysis for HUVECs-binding components of
YQFM
Compounds 1e7 could easily be identiﬁed as schisandrin, gin-
senoside Rb1, Rc, Rb2, Rd and 20(R)-Rg3 by comparing retention
time and the fragmentation behaviors with the standard sample
solution and the ﬁngerprint of YQFM, respectively. Among these
compounds, 20(S)-Rg3 was identiﬁed by comparing with literature
(26) and showed similar MS behaviors to 20(R)-Rg3 (Fig. 2A). In
addition, compound 8 and 9 were tentatively identiﬁed as a group
of geometric isomer. They showed the same [MeH] ions at m/z
765.4914, in the positive ion MS/MS spectra, they afforded ions at
m/z 587.4301, 443.3884, 425.3778, 407.3673 (Fig. 2B). Therefore,
they were tentatively identiﬁed as ginsenoside Rk1 and Rg5
according to publication (26).Fig. 2. ESI-MS ionization spectrum of compound 6 and compounds 8/9. (A) Full-scan produc
Full-scan product ion spectra of [MeH] ions (B1) and fragmentation pathways for compo3.3. Effects of schisandrin on H/R-induced injury in HUVECs
HUVECs were incubated with schisandrin (Fig. 3A) at concen-
trations of 0.1e100 mM and YQFM at 400 mg/mL for 12 h and
exposed to hypoxia of 4 h followed by 2 h reoxygenation. As shown
in Fig. 3B, the viability of HUVECs subjected to H/R was only 52.9%
compared to the untreated cells (P < 0.01). However, H/R induced
HUVECs injury was signiﬁcantly attenuated by pretreatment with
schisandrin in a concentration-dependent manner and YQFM. As
shown in Fig. 3C, the percentage of LDH, an indicator for cell
damage, was 12.7% in the control, which signiﬁcantly increased to
39.2% after H/R (P < 0.01). While pretreatment with schisandrin at
concentrations of 10e100 mM and YQFM signiﬁcantly inhibited the
increase in LDH release. These results indicated that schisandrin
had an obvious protective effect against H/R-mediated damage in
HUVECs.
3.4. Effects of schisandrin on MDA, NO content and intracellular
ROS of HUVECs subjected to H/R
MDA was one of the most frequently used indicators of lipid
peroxidation, which was indirectly involved in the degree of
damage to cells. When HUVECs were subjected to H/R injury, the
content of MDA increased remarkably (P < 0.01). Whereas, the
concentration of MDA signiﬁcantly decreased after pre-treated
with schisandrin (Fig. 4A). Meanwhile, compared to the control
group, NO secretion was markedly decreased in the H/R group
(P < 0.05). Following pre-treatment with schisandrin, the decrease
in H/R-induced NO production was inhibited in a dose-dependent
manner (Fig. 4B). Moreover, cells pretreated with schisandrin
showed a substantial reduction in ROS levels (Fig. 4C).
3.5. Effects of schisandrin on H/R induced cell apoptosis
To evaluate whether the protective effect of schisandrin corre-
lated to the anti-apoptotic mechanism, the expression of anti-
apoptotic and pro-apoptotic proteins were determined by west-
ern blot. There was a tendency of increase in expression of cleavedt ion spectra of [MeH] ions (A1) and fragmentation pathways for compound 6 (A2). (B)
unds 8/9 (B2).
Fig. 3. Chemical structure of schisandrin (A) and protective effects of schisandrin and YQFM on cell viability (B) and LDH activity (C) in HUVECs subjected to H/R injury. HUVECs
were pretreated with schisandrin at the concentration of 0.1e100 mmol/L and 400 mg/mL YQFM for 12 h and then exposed to hypoxia of 4 h followed by 2 h reoxygenation. Vit E was
used as a positive control drug. Cell viability was measured by the MTT assay described in method. The LDH was detected using LDH cytotoxicity assay kit. Results were obtained
from three independent experiments and were presented as mean ± SD. ##P < 0.01 vs. Control group without H/R, **P < 0.01 vs. group treated with H/R alone.
Fig. 4. Effects of schisandrin on MDA content (A), NO production (B) and intracellular ROS (C) in HUVECs subjected to H/R injury. HUVECs were pretreated with schisandrin at the
concentration of 0.1e100 mmol/L for 12 h and then exposed to hypoxia of 4 h followed by 2 h reoxygenation. MDA content and NO production were measured by assay kit. ROS levels
were determined using 20 , 70-dichloroﬂuorescein diacetate (DCFH-DA, Molecular Probes), then the cells were loaded with DCFH-DA for 30 min and visualized by ﬂuorescence
microscopy. Vit E was used as a positive control drug. Results were obtained from three independent experiments and were presented as mean ± SD. ##P < 0.01, #P < 0.05 vs. Control
group without H/R, *P < 0.05, **P < 0.01 vs. group treated with H/R alone.
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sions of Bcl-2/Bax was signiﬁcantly decreased (Fig. 5B). Whereas,
HUVECs treated with schisandrin could increase Bcl-2/Bax
expression and conversely decrease the expression of caspase-3under H/R conditions. The results implied that schisandrin had
protective effects against H/R-induced cellular injury by decreasing
the apoptosis rate, which offered some new information for the role
of schisandrin in the cardiovascular system.
Fig. 5. Effects of schisandrin on the up-regulation of caspase-3 (A) and down-regulation of the ratio of Bcl-2/Bax (B) induced by H/R on HUVECs. HUVECs were pretreated with
schisandrin at the concentration of 1e100 mmol/L for 12 h and then exposed to hypoxia of 4 h followed by 2 h reoxygenation. Protein expressions were tested by western blot.
Results were obtained from three independent experiments and were expressed as mean ± SD. ##P < 0.01 vs. Control group without H/R, *P < 0.05, **P < 0.01 vs. group treated with
H/R alone.
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Given the key role of endothelial cells in the cardiovascular
diseases (19,20), we chose HUVECs binding as an enrichment
method to explore the bioactive components present in YQFM.
Nine compounds containing eight ginsenosides were identiﬁed.
Recently, the clinical utilization of ginseng to treat cardiovascular
diseases has increased dramatically. Both in vitro and in vivo results
indicated that ginsenosides had potentially positive effects on
cardiovascular disease by means of their various properties
including antioxidation, vasomotor regulation, inﬂuencing various
ion channels and so on. Studies showed that myocardial infarction
after ischemia and reperfusion was preconditionally protected by
ginsenoside Rb1 (14). Dihydroginsenoside Rg3 could increase the
production of NO by increasing phosphorylation and expression of
eNOS (27). Moreover, evidence suggested ginsenoside Rd mediated
cardioprotective effect against MI/R-induced apoptosis via a
mitochondrial-dependent apoptotic pathway (28). These ﬁndings
indicated that HUVECs-HPLC-MS/MS was a reliable method for
screening potential bioactive compounds from complicated sys-
tems of TCMs. Due to the substantial evidence in the literature for
the use of ginsenosides in the treatment of cardiovascular disorders
(9), whereas little is reported about schisandrin, we further inves-
tigated the protective effect of schisandrin.
Schisandrin, the most abundant lignan present in Schisandra
chinensis (Turcz.) Baill, was previously reported to have the anti-
inﬂammatory activity by upregulation of heme oxygenase-1 via
PI3K/Akt and Nrf-2 signaling pathways (29). Other studies re-
ported its neuroprotective effect on the glutamate-induced
neuronal excitotoxicity and suggested that it was a potential
cognitive enhancer against Alzheimer's disease through anti-
oxidative action (30,31). Although some of these activities could
reﬂect by schisandrin, no previous studies have addressed its
speciﬁc effects on H/R-induced injury in HUVECs. H/R injuries are
common causes of mortality and play important roles in human
pathophysiology because they occur in clinical conditions such as
myocardial ischemia and stroke (32,33). During hypoxia and
reperfusion vascular endothelium is a primary site of ROS gener-
ation and target of injury. Therefore, cellular models of H/R have
been widely used to evaluate the effects of drugs or active com-
pounds (34,35).Endothelial cell injury caused by H/R plays a critical role in the
pathogenesis of cardiovascular diseases. The indicators of oxidative
stress-related cell injury were measured in the present study (36).
NO was known to be an important effector molecule that had
gained recognition as a crucial modulator of vascular disease (37). It
was reported that NO had protective effects against apoptosis in a
variety of cell types including endothelial cells. In normal physio-
logical conditions, ROS generated from metabolic processes are
scavenged by antioxidants that are part of cellular defense mech-
anisms. However, in disease states such as H/R, overproduction of
ROS results in oxidative cellular damage (33). ROS cause oxidation
of proteins, affect singnal transduction pathways and ﬁnally result
in alterations of cardiac function, cellular injury and death (38). Our
ﬁndings ﬁrst demonstrated that schisandrin could protect against
H/R-induced HUVECs injury by increasing cell viability, NO content
and decreasing LDH leakage, MDA content and ROS generation,
which was beneﬁcial for the prevention and treatment of cardio-
vascular diseases. Vitamin E, which is a chain-breaking antioxidant,
was used as a positive control drug. Pretreatment with vitamin E
has been demonstrated to attenuate hypoxia/reoxygenation injury
in cardiomyocytes (39,40).
In addition, we further explored its possible mechanism of
schisandrin on cell injury induced by H/R. A balance between cell
proliferation and death is critical for tissue homeostasis in multi-
cellular organisms. Many diseases are more or less associated with
apoptosis, including cardiovascular diseases. Endothelium is a
critical site for the control of apoptosis and the suppression of
endothelial cell apoptosis is required for the maintenance of blood
vessel integrity (22). Caspase-3 is the key downstream enzyme and
the ﬁnal step of apoptotic pathway, and it can cause DNA degra-
dation and apoptosis when it is activated. The Bcl-2 family,
comprised of both anti-apoptotic proteins, such as Bcl-2, and pro-
apoptotic members, such as Bax, constitutes a critical intracellular
checkpoint for apoptosis within a common cell death pathway. The
balance between these proteins is essential for cell survival against
H/R injuries (41). Our results showed that schisandrin could in-
crease Bcl-2/Bax expression and conversely decrease the expression
of caspase-3 under H/R conditions, which indicated that schisan-
drin had protective effects against H/R-induced cellular injury by
decreasing the apoptosis rate. It is noteworthy that the ﬁndings of
the present study may shed light on the pharmacological basis for
F. Li et al. / Journal of Pharmacological Sciences 129 (2015) 1e8 7the clinical application of traditional Chinesemedicine in treatment
of cardiovascular diseases relevant to the endothelial cell damage.
Further studies on the understanding of schisandrin targets and its
molecular mechanism are needed.
Additionally, we investigated the effects of identiﬁed nine
compounds against H/R-mediated injury in HUVECs. As seen in
Supplemental Fig. 1, pretreatment with schisandrin, ginsenoside
Rb1, Rc, Rb2, Rd, (R)-Rg3 at the concentration of 10 mM signiﬁcantly
increased the cell viability, while pretreatment with ginsenosides
(S)-Rg3 and Rk1/Rg5 at 10 mMdid not exert obvious protective effect
against H/R-mediated damage in HUVECs. We then determined the
content of schisandrin in YQFM as about 0.09047 ± 0.0009 mg/g.
The maximum concentration of schisandrin at 100 mM was equiv-
alent to 43.25 mg/mL in our experiment. Moreover, the content of
schisandrin in YQFM at concentration of 400 mg/mL was far lower
than 43.25 mg/mL. Yet, YQFM presented an excellent protective
effect, due to complicated synergistic or integrated actions of
multiple active compounds.
In conclusion, this combined speciﬁc binding and HPLC-ESI-MS/
MS analysis method was applied to screen for potential bioactive
components in YQFM via vascular endothelial cell receptors or
other targets. Schisandrin, a compound identiﬁed by this method,
was ﬁrst demonstrated to exert protective effects against H/R-
induced vascular endothelial injury by inhibiting apoptosis
pathway. These ﬁndings argue that the cardiovascular protective
effect of YQFM is at least partially mediated by schisandrin. In
addition, some ginsenosides with deﬁnite cardiovascular protective
effect were also detected, which indicated that HUVECs extract and
HPLC-ESI-MS/MS analysis would be very efﬁcient and rapid for
screening and identiﬁcation of bioactive components in YQFM.
These results present the prospective application of this method to
other complicated systems of TCMs. More research data are urged
to be accumulated in the further investigation.
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